Catabasis Pharmaceuticals (CATB)

[harr449]

ATXS new ticker.

[ErnieBilco]

Cause it ain't gonna stay this high.

[Disquisition]

UNHINGED DUMPING

[Tzr250rg]

lets see if this can hold today and keep climbing, the 50 crossed over the 200 yesterday

[Tzr250rg]

why the decline with Black rock, Perceptive, Xontogeny, Viridian and etc buying?

[stock1ace1]

Yes it is data coming tomorrow !

[iidris]

Started to move.

[slow_feet]

SI as of 2/12/21

Report Date	Total Shares Sold Short 
 2/12/2021	2,390,000 shares 
 1/29/2021	1,130,000 shares 
 1/15/2021	1,240,000 shares 
 12/31/2020	1,920,000 shares 
 12/15/2020	1,920,000 shares 
 11/30/2020	  470,000 shares 
 11/15/2020	  444,200 shares 
 10/30/2020	  644,100 shares

[slow_feet]

Total Offering Amount $175,738,599 USD: The Acquisition of Quellis Biosciences, Inc. continues...

[0210]

+60% to $3.95 on >200x DMAV and >14x O/S. Another MOASS (quietly)in-the-making, hmmmmmmmmm........

[ClayTrader]

* * $CATB Video Chart 01-29-2021 * *

Link to Video - click here to watch the technical chart video

[slow_feet]

That and/or the "insiders" and their buds who knew in advance about the Quellis acquisition. I'm always looking for the "mystery blocks" so I can join them.

[alwaysthankfull]

Must be BLACKROCK and Federated Hermes, and many more!

[alwaysthankfull]

CATB, 20 million S/OS as of 10/30/20. Wide vertical space to leap just like a cat! $CATB

[slow_feet]

Yep, and the Calls are doing doing excellent!

[Docstemcell2020]

Nice

[slow_feet]

Quellis Biosciences, Inc.

Management

Jonathan Violin, Ph.D. – Founder and President
Jonathan joined Quellis shortly after its incorporation to lead its launch and growth. He is a partner at Viridian LLC, a biotech incubator that builds virtual drug discovery companies to pursue product-focused drug discovery hypotheses. Prior to joining Viridian, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. While there, he held a series of roles including leadership of discovery biology, investor relations, corporate strategy, and scientific affairs. He has helped identify and progress four novel molecules into clinical development, including one program granted Breakthrough Therapy Designation by the FDA. He also has experience in alliance management, business development, and regulatory interactions including team lead and moderator for a new chemical entity FDA Advisory Committee. Jonathan has co-authored over 45 peer-reviewed publications. He holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.

Vahe Bedian, Ph.D. – Founder and Chief Scientific Officer
Vahe joined Quellis at its inception and is responsible for research and discovery. He is a partner at Viridian LLC, a biotech incubator that builds virtual drug discovery companies to pursue product-focused drug discovery hypotheses. Vahe previously served for 10 years at AstraZeneca focused on antibody therapeutics and immuno-oncology, most recently as Director, Search and Evaluation, Global Product and Portfolio Strategy. His other roles at AstraZeneca included site lead for a biologics discovery group, helping to oversee oncology and technology portfolios, and supporting the AstraZeneca-MedImmune integration. Prior to this, Vahe spent 8 years at Pfizer where he helped established the company’s biologics strategy across therapeutic areas and led discovery efforts for clinical development teams responsible for four INDs and a Phase 3 program. Vahe has authored more than 40 publications. He holds a Ph.D. in Biophysics from SUNY Buffalo and a M.S. and B.S. in Physics from the American University of Beirut.

About

Focused on Designing Meaningful Medicines

Quellis was founded to deliver best-in-class therapies to patients suffering serious rare diseases – and underserved by current treatment options. The Company is based in Boston, and is led by partners from the biotech incubator Viridian LLC in collaboration with team at biotech accelerator Xontogeny LLC, and with funding from the Perceptive Xontogeny Venture Fund. The Quellis team has deep experience in mAb discovery and development, company creation, and private and public biotech investment. Our shared goal is to create meaningful medicines for every disease we target.

The lead Quellis program targets a life-threatening and burdensome rare disease. Approved medications leave substantial unmet needs for these patients; Quellis is pursuing a product-focused hypothesis to discover a new molecule with best-in-class performance. The Company is currently optimizing several new monoclonal antibodies (mAbs) leveraging a validated mechanism of action. We are engineering these mAbs to include features intended to deliver greater value and improve patients’ lives. As part of these efforts, the Company plans to incorporate Xencor, Inc.’s Xtend™ Fc technology, for which the Company holds a target-exclusive license from Xencor. Xtend is a clinically proven antibody technology that provides for improved antibody half-life and thereby reduces the size and frequency of doses that patients require compared to a standard antibody drug candidate.

Board of Directors

Chris Garabedian, Chairman
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept. In 2017, Chris joined Perceptive Advisors to develop their Venture Fund strategy and launched the Perceptive Xontogeny Venture Fund in 2018 to support early stage companies seeded and incubated at Xontogeny and other ventures.

Chris has a broad base of experience and a track record of success over his decades long experience in the biopharma industry. Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris led Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global commercial and corporate development leadership roles at Gilead from 1997 to 2005.

Chris serves on a number of Boards of life sciences companies and speaks at industry conferences on a wide range of important issues. Chris is also on the Board of Directors of MassBio and serves as a Senior Advisor for the Boston Consulting Group.

Fred Callori
Fred joined Xontogeny in September 2017 as SVP, Corporate Development. Fred’s responsibilities include due diligence, deal structuring and negotiation, company formation, and the operational oversight and management of Xontogeny’s seed investments. He provides corporate governance, transactional and strategic advice to Xontogeny’s portfolio of companies and serves on several portfolio company Boards. In 2018, Fred joined the Perceptive Xontogeny Venture Fund to support fund investments, including continued investments in companies seeded and incubated at Xontogeny.

Prior to joining Xontogeny, Fred was a Partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP, a Boston law firm ranked among the most active firms worldwide for private equity and venture capital deals. During his 20-year tenure at Choate, Fred developed deep expertise in the formation, structure, financing and overall corporate development of early stage and emerging life science companies, including representing leading venture capital and institutional investment firms focused on investing in the sector.

Fred holds a JD from Boston University School of Law and a BA in Economics from Binghamton University.

Jonathan Violin, Ph.D.
Jonathan joined Quellis shortly after its incorporation to lead its launch and growth. He is a partner at Viridian LLC, a biotech incubator that builds virtual drug discovery companies to pursue product-focused drug discovery hypotheses. Prior to joining Viridian, Jonathan co-founded and helped lead Trevena Inc. from discovery research through clinical development and NDA submission, including multiple rounds of venture and public financing. While there, he held a series of roles including leadership of discovery biology, investor relations, corporate strategy, and scientific affairs. He has helped identify and progress four novel molecules in to clinical development, including one program granted Breakthrough Therapy Designation by the FDA. He also has experience in alliance management, business development, and regulatory interactions including team lead and moderator for a new chemical entity FDA Advisory Committee. Jonathan has co-authored over 45 peer-reviewed publications. He holds a Ph.D. from the Department of Pharmacology at the University of California, San Diego, an M.B.A. from the Fuqua School of Business, and a B.S. in Chemical Pharmacology from Duke University.

12/10/19: Quellis Biosciences Inc. Announces $17 Million Series A Financing

http://web.archive.org/web/20201201021841/https://quellisbio.com/

[slow_feet]

12/23/20: Again, the large mystery buying blocks...

[0210]

You Called It, ClayTrader: Turbo-Charged Penny Stock Plays(PSP).
Holding 10 CATB Call Option Contracts @$2.50 Strike Price. Expiry Date: 7-16-2021.

Average Cost per Share(ACPS) $0.812 (vs. current $1.08 pps = +33% in 1 day, as a turbo-charged PSP!!!

CATB Break Even Price $3.31 ($2.50 Strike Price + ACPS 0.812 = $3.31)

CALL Options Contract w $2.50 SP by 07-16-2021: Bid $0.95 x 9 vs. Ask $1.20 x 204
The Stock: $2.17(12-11-2020, Friday), while its $2.50 Call Option Contracts last traded @$1.08 per Contract = +33% from previous trading day.

[slow_feet]

Buying volume showing up.

[ClayTrader]

* * $CATB Video Chart 12-02-2020 * *

Link to Video - click here to watch the technical chart video

[Spanked-It]

Looking good! Heading north!

[stocksrising]

What’s up with the PM move?

[AaronTrades]

This is my favorite stock right now! Check out my video on it:

[TheFinalCD]

1.56 CATB on watch



im already in BVXV and taking a beating


might as well buy another bag

[ErnieBilco]

Talk about oversold - RSI 8 on 90 times normal volume.

[ClayTrader]

* * $CATB Video Chart 10-27-2020 * *

Link to Video - click here to watch the technical chart video

[0210]

$1.56 vs. $2.78 cash & equivalents a/o 9-30-2020($52.9m/19m OS = $2.78).

SOURCE: CATB reporting Q3 in November, 2020; as of Sept. 30, the company notes it had cash and equivalents of about $52.9M.

[0210]

added 1.50s to my 1.70s.

[ErnieBilco]

Grabbed the falling knife here.

[Liquid1974]

Added for bounce this a.m...

[doolz]

Guess nobody knows what’s up yet

[stocksrising]

WHATs going on with this Co.?

[Chrism0000]

Did I see someone bought 159000 shares!!!!!!

[nole92]

Phase 3 trials underway to be completed in June 2020. Results in Q4 2020.

https://clinicaltrials.gov/ct2/show/NCT03703882?term=edasalonexent&cond=Duchenne+Muscular+Dystrophy

[nole92]

Edasalonexent (formerly CAT-1004) is an oral and small molecule experimental therapy being developed by Catabasis Pharmaceuticals to treat all forms of Duchenne muscular dystrophy (DMD).

How edasalonexent works
DMD is one of the most common types of muscular dystrophy. It primarily affects boys and leads to the progressive loss of muscle fibers. The condition is caused by a mutation that results in a lack of dystrophin protein production. This protein provides structure to muscle fibers and protects them against injury. Without dystrophin, muscle fibers get damaged at each contraction.

A signaling pathway called the NF-kappa B pathway is activated in DMD patients from infancy. This pathway is responsible for muscle fiber breakdown, and the failure to repair muscle injuries that are seen in DMD patients.

Edasalonexent inhibits NF-kappa B, blocking the pathway. Through this mechanism, it is thought that edasalonexent may be able to preserve muscle function in DMD patients.

Edasalonexent in clinical trials
A combined Phase 1/2 clinical trial (NCT02439216) called MoveDMD evaluated the safety, efficacy, and pharmacokinetics (how the treatment moves in the body) of edasalonexent in children with a genetically confirmed diagnosis of DMD. A total of 31 boys, ages 4 to 8, were enrolled.

Edasalonexent preserved muscle function and substantially slowed DMD disease progression through 60 weeks of treatment compared to placebo. Consistent improvements in all assessments of muscle function were observed after more than a year of treatment. Edasalonexent was well-tolerated with no safety signals observed in the trial.

A Phase 3 clinical trial to further test edasalonexent is now underway. This 52-week trial, PolarisDMD (NCT03703882), is a multi-center trial with test sites in the U.S., Canada, Asia, and Australia.

PolarisDMD aimed to recruit 125 boys, ages 4 to 7, who have not been treated with corticosteroids for at least six months. The study actually exceeded this recruitment target due to high demand and enrolled 130 participants and is no longer enrolling. Patients were randomized, 2:1, to receive either edasalonexent (100 mg/kg capsule) or placebo daily. Patients will have clinical visits every three months, and the study’s primary goal is to measure the change in North Star Ambulatory Assessment scores at one year. This includes tests that measure the time it takes the children to stand, the four-stair climb test, and the 10-meter walk/run test. The boys’ muscle strength and growth, as well as their heart and bone health, will also be assessed. No muscle biopsies or magnetic resonance imaging (MRI) will be required for this study. The trial is expected to conclude in June 2020.

After 12 months, patients will be invited to continue receiving edasalonexent, or begin treatment, in an open-label extension study, GalaxyDMD (NCT03917719). The study is open to patients involved in the MoveDMD or PolarisDMD trials or DMD-affected siblings of boys enrolled in those trials. GalaxyDMD will follow the participants for up to 104 weeks (2 years) and is expected to complete in June of 2020.

Other information
The U.S. Food and Drug Administration (FDA) granted edasalonexent orphan drug, rare pediatric disease, and fast track designations. The European Commission (EC) also granted the treatment orphan medicinal product designation for the treatment of DMD.

[whytestocks]

News: $CATB Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be presented at the 24 th International Congress ...

In case you are interested CATB - Catabasis Pharmaceuticals to Present the MoveDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy at the 24th International Congress of the World Muscle Society

[whytestocks]

News: $CATB Catabasis Pharmaceuticals Presents Preclinical Data Showing Potential for Bone Preservation with Edasalonexent in Duchenne Muscular Dystrophy

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy...

In case you are interested https://marketwirenews.com/news-releases/catabasis-pharmaceuticals-presents-preclinical-data-showing-potential-for-bone-preservation-with-edasalonexent-in-duchenne-muscular-dystrophy-8395012.html

[whytestocks]

News: $CATB Catabasis Pharmaceuticals to Present at Upcoming Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and Parent Project Muscular Dystrophy 25th Annual Conference

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy (DMD), at two upcoming meetings: the Symposium on M...

Read the whole news https://marketwirenews.com/news-releases/catabasis-pharmaceuticals-to-present-at-upcoming-symposium-on-muscle-bone-interaction-in-duchenne-muscular-dystrophy-and-parent-project-muscular-dystrophy-25th-annual-conference-8373896.html

[LiveLife]

= CATB = Moved to BUY on Swing Trading Watch list - https://investorshub.advfn.com/boards/read_msg.aspx?message_id=145154054

GLTA

[Klinsmann]

Perfect buy-in @0,60 as it seems - nice day so far for CATB!

[Klinsmann]

Good news, time to buy right now!

[Klinsmann]

Still on watch - it´s settling during the last days

[Klinsmann]

Great day so far - looks like 1$ possible this week

[Pentium]

Potential for P3 trial and company overall.

I've been researching all weekend about this company.

What is the potential of P3 completion. What kind of value would the market be for this Polaris DMD treatment overall. Seems to be limited applications so smaller breakthrough?

Assuming all goes perfectly with P3 completion and FDA approval and drug on the market does this make Catabasis 300M? 500M? 1B+?

Trying to gauge risk/reward.

Thanks in advance.

[janeyH]

What, you here again, we must be using very similar screening techniques.

[THREE-DAY-TRADER]

$CATB ~ Amazing it broke prior .75 resistance. High near .78 so far on 8/29. $CATB = Latest Success for Following Subscribers = Alerted Entry 8/17/18 @ 65 Limit.

Prior Recent Successes = $NV*X, $D*W, $GB*C....
(A Variety Of Market Areas Traded)

***New Trades Available for My Private E-Mail Followers***
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142998931



$CATB Chart as of 8/29/18:

[THREE-DAY-TRADER]

$CATB = New Recent high of .75!! My private followers got this alerted August 17 @ .65 Limit or less entry a week ago. Followers privately had the ability to enter it .61-.65 for 4 days before $CATB broke out higher.

My post below about this from 8/22/18, pointing out .61+ support & that $CATB was breaking above .65 resistance & that much higher was next likely:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143094205

----------------------------------------------------------------------------

To Inquire Sign Up, Go Here for my next trades:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=142998931


My last trade recently for followers was $NV*X:
Private Followers Profited on $NV*X August 9 - 13 (in a Short Period Of Time for a gain range of 20-35%) from 1.19 Limit entry before it flew up to 1.55 after it announced quarterly earnings



$CATB ~ Live chart:

[THREE-DAY-TRADER]

$CATB ~ Nice progressive movement since Monday (8/20).
Broke above .65+ yesterday (8/22) which I pointed out yesterday, & held above that today to newer short term highs (.71+ area so far) with steadily increasing volume.
Nice set up here for a potential break out much higher yet.
If it can break above .71+ resistance (as of late afternoon today ~ 8/23), a good chance it shoots up to .78 & then .80+ area could be next.

My post below about this from 8/22/18:
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=143094205




$CATB ~ Live chart:

[THREE-DAY-TRADER]

$CATB ~ Holding above .61+ support after multiple support area re-tests ever since about August 3, & now today showing some improved, progressive price movement (high so far of .69 today - August 22).

Buying Volume stealthily increasing ever since it recently last re-retested .61+ support on August 21 (Monday) while RSI + MACD shaping up into early stage bullish formations.
Showing good potential for a break out higher soon as long as it can hold .65+ or more going forward after today (8/22).